Merck raises full-year guidance again following strong quarter

Among the growth drivers in the portfolio is the multiple sclerosis drug Mavenclad, which had grown continuously in recent quarters. In addition, the segment around AI semiconductor materials is driving business development, where Merck supplies specialty chemicals for the chip industry.

Growth drivers Mavenclad and semiconductor materials

Within the group, the question is also being discussed of how the upward revision compared with the most recently communicated full-year targets will affect the medium-term strategy. Analysts pointed out that the new guidance leaves room for further organic growth.

The news was received positively in the markets. The Merck share rose noticeably after the raised full-year targets became known, supported by confirmation from several analyst houses. Derivative products such as knock-out leveraged certificates on the Merck share were also included in trading.

Reaction from analysts and the share

Among observers, Jefferies & Company in particular highlighted the latest results. James Vane-Tempest, an analyst at the firm, described the development as further evidence of the group's operational strength. The Jefferies assessment is among the most frequently quoted reactions to the quarterly statement.

For the second half of 2026, Merck continues to expect further growth on the existing basis. According to its own statements, the group considers itself well positioned to reach the raised targets and is also monitoring possible burdens from the trade policy environment.

Outlook on the full year

The Group's management, led by board member Kai Beckmann, sees the renewed raising of the full-year targets also as a signal to investors that the previous strategy is taking hold. According to the company, the outlook for the full year remains dependent on economic and trade policy framework conditions, with the recently observed tariff effects classified as manageable.

With the forecast revision, Merck underscores that the company remains on a growth course despite macroeconomic uncertainties. The second raising of full-year targets within a financial year is viewed by observers as a signal of confidence in the operating business.

Investors and analysts will examine upcoming quarterly reports for indications of whether the elevated target level can be maintained or revised again in the further course. If the positive trend in Mavenclad and in the semiconductor materials business continues, market observers expect stable or further rising guidance.